Gilead Sciences, Inc (GILD)

Etorro trading 970x250
Gilead Sciences, Inc (GILD) Logo

About Gilead Sciences, Inc

Gilead Sciences, Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of human immunodeficiency virus (HIV) infection; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of hematology, oncology, and cell therapy patients. In addition, the company provides Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; Ranexa, an oral formulation for the treatment of chronic angina; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. Gilead Sciences, Inc. has collaboration agreements with Arcus Biosciences, Inc.; Pionyr; Tizona; Tango Therapeutics, Inc.; Jounce Therapeutics, Inc.; Galapagos; Janssen; Japan Tobacco, Inc.; Gadeta; Bristol-Myers Squibb Company; Merck; and Novo Nordisk A/S. The company was founded in 1987 and is headquartered in Foster City, California. Address: 333 Lakeside Drive, Foster City, CA, United States, 94404

Gilead Sciences, Inc News and around…

Latest news about Gilead Sciences, Inc (GILD) common stock and company :

U.S. Food and Drug Administration Approves Expanded Indication of Gilead’s Biktarvy® for Treatment of HIV-1 in Pediatric Populations
18 Oct, 2021 FinancialContent

Gilead Sciences, Inc. (Nasdaq: GILD) today announced the U.S. Food and Drug Administration (FDA) approved a new low-dose tablet dosage form of Biktarvy® (bictegravir 30 mg/emtricitabine 120 mg/tenofovir alafenamide 15 mg tablets) for pediatric patients weighing at least 14 kg to less than 25 kg who are virologically suppressed or new to antiretroviral therapy. The approval of this supplemental New Drug Application (sNDA) expands the indication for Biktarvy to include younger children living with HIV-1 infection and will help to close the gap between HIV treatment options available for adults and children.

2 Tricks and a Treat for Gene Therapy Investors
18 Oct, 2021 FinancialContent

It looks like the gene therapy market is a haunted house, but growing biotech Repligen might be the treat investors need this Halloween.

2 Top Healthcare Stocks That Could Be Bought Out in 2022
16 Oct, 2021 FinancialContent

These two novel-drug makers could be top takeover targets next year.

Crispr: A Fallen Angel In Gene Editing
16 Oct, 2021 FinancialContent

As with most promising biotech companies, investors bid their prices up for CRSP based on its potential for early profits. When the payoff didn't occur on schedule, investors bailed out. Once it becomes profitable, investors will come flocking back.

NIH Director on FDA ‘being careful’ in clearing Moderna vaccine for kids 12-17
15 Oct, 2021 Yahoo! Finance

Dr. Francis Collins, Outgoing NIH Director, joins Yahoo Finance’s Anjalee Khemlani to discuss Covid-19 vaccine production, drug development research, and misinformation surrounding Covid-19 vaccines.

James Morrow’s Callodine Capital Portfolio: Top 10 Picks
15 Oct, 2021 Yahoo! Finance

In this article, we will discuss the top 10 stock picks of James Morrow’s Callodine Capital. If you want to skip our detailed analysis of Morrow’s history, investment philosophy, and hedge fund performance, go directly to James Morrow’s Callodine Capital Portfolio: Top 5 Picks. Callodine Capital Management is the investment arm of the Callodine Group, […]

Sacituzumab Govitecan Receives Positive CHMP Opinion as 2L Treatment for Adult Patients With Metastatic Triple-Negative Breast Cancer
15 Oct, 2021 FinancialContent

Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion for sacituzumab govitecan as monotherapy indicated for adult patients with unresectable or metastatic triple-negative breast cancer (TNBC) who have received two or more prior systemic therapies, at least one of them for advanced disease. The final European Commission decision on the Marketing Authorization Application for sacituzumab govitecan is anticipated later in 2021.

Gilead Sciences to Release Third Quarter 2021 Financial Results on Thursday, October 28, 2021
14 Oct, 2021 FinancialContent

Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its third quarter 2021 financial results will be released on Thursday, October 28, after the market closes. At 4:30 p.m. Eastern Time that day, Gilead’s management will host a webcast to discuss the company’s third quarter 2021 financial results and will provide a business update.

Doctor on Covid-19: ‘Let history guide our future actions’
14 Oct, 2021 Yahoo! Finance

Dr. Stella Safo, NYC-based HIV Primary Care Physician, joins Yahoo Finance to discuss the latest in the coronavirus pandemic.

Noteworthy Thursday Option Activity: WHR, GILD, CRM
14 Oct, 2021 FinancialContent

Looking at options trading activity among components of the S&P 500 index, there is noteworthy activity today in Whirlpool Corp (WHR), where a total volume of 7,196 contracts has been traded thus far today, a contract volume which is representative of approximately 719,600 underlying shares (given that every 1 contract represents 100 underlying shares). That number works out to 117.9% of WHR's average daily trading volume over the past month, of 610,200 shares..

Will Gilead (GILD) Beat Estimates Again in Its Next Earnings Report?
14 Oct, 2021 Yahoo! Finance

Gilead (GILD) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Noteworthy ETF Outflows: IBB, GILD, REGN, ILMN
14 Oct, 2021 FinancialContent

Symbols mentioned in this story: IBB, GILD, REGN, ILMN Exchange traded funds (ETFs) trade just like stocks, but instead of ''shares'' investors are actually buying and selling ''units''. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand..

This Company Revolutionizes What Matters for Hospitals, Big Pharma and Health Insurers
14 Oct, 2021 FinancialContent

You can perch on a 1-legged stool and balance precariously on 2, but if you want to settle in with comfort and safety, you need 3 sturdy ...

What Kind Of Shareholders Own Gilead Sciences, Inc. (NASDAQ:GILD)?
14 Oct, 2021 Yahoo! Finance

A look at the shareholders of Gilead Sciences, Inc. ( NASDAQ:GILD ) can tell us which group is most powerful. Large...

U.S. to open Canada, Mexico borders for vaccinated visitors
13 Oct, 2021 Yahoo! Finance

Dr. Rishi Desai, Chief Medical Officer at Osmosis & Former Center for Disease Control and Prevention Epidemic Intelligence Officer, joins Yahoo Finance to discuss the latest in the coronavirus pandemic.

CRSP Stock: The Cancer Study News Sending Crispr Therapeutics Lower Today
13 Oct, 2021 FinancialContent

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Crispr Therapeutics (CRSP) stock is falling on Wednesday following the release of new results from a Phase 1 clinical trial. The post CRSP Stock: The Cancer Study News Sending Crispr Therapeutics Lower Today appeared first on InvestorPlace. More From InvestorPlace Stock Prodigy Who Found NIO at $2… Says Buy THIS Now Analyst Who Found Microsoft at $0.38 Names #1 Pick for the AI Boom America’s #1 EV Stock Still Flying Under the Radar

Why CRISPR Therapeutics Stock Is Sinking Today
13 Oct, 2021 FinancialContent

Investors aren't impressed with the early-stage results from the biotech's lead cancer therapy candidate.

Pushing back on businesses’ ability to have a vaccine mandate is a bad idea: Doctor
12 Oct, 2021 Yahoo! Finance

Dr. Ali Raja, Professor at Harvard Medical School, joins Yahoo Finance Live to discuss the latest in the coronavirus pandemic.

Interns Help Facilitate Breast Cancer Conversations Among Young Black Women
12 Oct, 2021 Yahoo! Finance

Taylor McKay, a senior at Florida A&M University, always knew she wanted to become a surgeon. But it wasn’t until she did an internship with TOUCH: The Black Breast Cancer Alliance, that she decide...

Molnupiravir? Not So Fast. What About Tollovir? — Here's Why You Should Know What That Means
12 Oct, 2021 FinancialContent

Photo by Martin Sanchez on Unsplash Merck (NYSE: MRK) announced last Friday impressive results from its COVID-19 antiviral, ...

Biotech Stocks Are Lagging, Is It Time to Rebalance Your Healthcare Portfolio?
11 Oct, 2021 FinancialContent

You may have seen that biotech stocks have been in a funk. The IBB has broken through the SMA-200 support line near $160 and it holds a perilous perch at $155, up only about 2.5% year-to-date. The IBB has been down over 10% for the past 30 days.

Studies claim Pfizer vaccine is less effective after a few months
08 Oct, 2021 Yahoo! Finance

Dr. Payal Patel, Infectious Diseases Physician, University of Michigan, joins Yahoo Finance to discuss the latest on the coronavirus pandemic.

Moderna Stock Looks Fully Valued Here, But It Has a Great Future
08 Oct, 2021 FinancialContent

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Moderna has a host of vaccines in its pipeline, including against cancer and HIV. It's not a one-trick pony. The post Moderna Stock Looks Fully Valued Here, But It Has a Great Future appeared first on InvestorPlace. More From InvestorPlace Stock Prodigy Who Found NIO at $2… Says Buy THIS Now Analyst Who Found Microsoft at $0.38 Names #1 Pick for the AI Boom America’s #1 EV Stock Still Flying Under the Radar

10 Best Big Pharma Stocks to Buy Now
08 Oct, 2021 Yahoo! Finance

In this article, we discuss the 10 best big pharma stocks to buy now. If you want to skip our detailed analysis of these stocks, go directly to the 5 Best Big Pharma Stocks to Buy Now. On September 9, the United States Department of Health and Human Services (HHS) unveiled a comprehensive plan to reduce drug […]

'Vaccine mandates are proving to work’: Doctor on Covid-19
07 Oct, 2021 Yahoo! Finance

Dr. Steven McDonald, Emergency Medicine Physician, joins Yahoo Finance to discuss the latest on the coronavirus pandemic.

Mixing & matching covid boosters ‘might be a great opportunity’: Doctor
06 Oct, 2021 Yahoo! Finance

Dr. Jeremy Faust, Emergency Medicine Physician, Brigham and Women’s Hospital, joins Yahoo Finance to discuss the latest on the coronavirus pandemic.

The Zacks Analyst Blog Highlights: Apple, Mastercard, Verizon, Target and Gilead Sciences
06 Oct, 2021 Yahoo! Finance

The Zacks Analyst Blog Highlights: Apple, Mastercard, Verizon, Target and Gilead Sciences

Merck May Beat Pfizer to the COVID Pill Market. Does It Matter?
06 Oct, 2021 FinancialContent

Merck is ready to apply for authorization ahead of Pfizer.

Why Gilead Sciences Investors Shouldn't Give Up on Remdesivir Just Yet
06 Oct, 2021 FinancialContent

A new study shows it is highly effective in preventing deaths if taken early.

Could Pfizer's COVID Pill Be Better Than Merck's?
06 Oct, 2021 FinancialContent

The best answer, for now, is maybe.

Gilead Sciences, Inc (GILD) is a NASDAQ Common Stock listed in , ,

970x250